Page 90 - Read Online

Skotnicki AB. Premature cardiovascular mortality in [Last accessed on 2015 Apr 27].
lymphoma patients treated with (R)-CHOP regimen - a 34. Gisselbrecht C, Haioun C, Lepage E, Bastion Y, Tilly H,
national multicenter study. Int J Cardiol 2013;168:5212-7. Bosly A, Dupriez B, Marit G, Herbrecht R, Deconinck E,
23. Hortobágyi GN. Anthracyclines in the treatment of cancer. An Marolleau JP, Yver A, Dabouz-Harrouche F, Coiffi er B, Reyes F.
overview. Drugs 1997;54 Suppl 4:1-7. Placebo-controlled phase III study of lenograstim (glycosylated
24. Hershman DL, McBride RB, Eisenberger A, Tsai WY, recombinant human granulocyte colony-stimulating factor)
Grann VR, Jacobson JS. Doxorubicin, cardiac risk factors, in aggressive non-Hodgkin’s lymphoma: factors infl uencing
and cardiac toxicity in elderly patients with diffuse B-cell chemotherapy administration. Groupe d’Etude des Lymphomes
non-Hodgkin’s lymphoma. J Clin Oncol 2008;26:3159-65. de l’Adulte. Leuk Lymphoma 1997;25:289-300.
25. van de Schans SA, Wymenga AN, van Spronsen DJ, 35. Amadori D. Moving forward with new data and approaches:
Schouten HC, Coebergh JW, Janssen-Heijnen ML. Two sides of a fresh look at anthracyclines in non-Hodgkin’s lymphoma.
the medallion: Poor treatment tolerance but better survival by Hematol Rep 2011;3:e1.
standard chemotherapy in elderly patients with advanced-stage 36. Schmitt CJ, Dietrich S, Ho AD, Witzens-Harig M.
diffuse large B-cell lymphoma. Ann Oncol 2012;23:1280-6. Replacement of conventional doxorubicin by pegylated
26. Peters FP, Fickers MM, Erdkamp FL, Wals J, Wils JA, liposomal doxorubicin is a safe and effective alternative in the
Schouten HC. The effect of optimal treatment on elderly treatment of non-Hodgkin’s lymphoma patients with cardiac
patients with aggressive non-Hodgkin’s lymphoma: more risk factors. Ann Hematol 2012;91:391-7.
patients treated with unaffected response rates. Ann Hematol 37. Visani G, Isidori A. Nonpegylated liposomal doxorubicin in
2001;80:406-10. the treatment of B-cell non-Hodgkin’s lymphoma: where we
27. Nicolaides C, Dimou S, Pavlidisa N. Prognostic factors stand. Expert Rev Anticancer Ther 2009;9:357-63.
in aggressive non-Hodgkin’s lymphomas. Oncologist 38. Lambertenghi Deliliers G, Butti C, Baldini L, Ceriani A,
1998;3:189-97. Lombardi F, Luoni M, Montalbetti L, Pavia G, Pinotti G,
28. Khaled HM, Zekri ZK, Mokhtar N, Ali NM, Darwish T, Elattar I, Pogliani E, Vanoli P. A cooperative study of epirubicin with
Gaafar R, Moawad MS. A randomized EPOCH vs. CHOP cyclophosphamide, vincristine and prednisone (CEOP) in
front-line therapy for aggressive non-Hodgkin’s lymphoma non-Hodgkin’s lymphoma. Haematologica 1995;80:318-24.
patients: long-term results. Ann Oncol 1999;10:1489-92. 39. Vose JM, Weisenburger DD, Lynch JC, Bierman PJ, Chan JC,
29. Burton C, Smith P, Vaughan-Hudson G, Qian W, Hoskin P, Bast M, Aoun P, Bociek G, Greiner T, Armitage JO; Nebraska
Cunningham D, Hancock B, Linch D. Comparison of Lymphomas Study Group. CNOP for diffuse aggressive
CHOP versus CIOP in good prognosis younger patients non-Hodgkin’s lymphoma: the Nebraska lymphoma study
with histologically aggressive non-Hodgkin lymphoma. Br J group experience. Leuk Lymphoma 2002;43:799-804.
Haematol 2005;130:536-41. 40. Mukherji D, Pettengell R. Pixantrone maleate for non-Hodgkin’s
30. Hallack Neto AE, Pereira J, Beitler B, Chamone DA, lymphoma. Drugs Today (Barc) 2009;45:797-805.
Llacer PD, Dulley FL, Chaoubah A. Results of CHOP 41. Fields PA, Townsend W, Webb A, Counsell N, Pocock C,
chemotherapy for diffuse large B-cell lymphoma. Braz J Med Smith P, Jack A, El-Mehidi N, Johnson PW, Radford J,
Biol Res 2006;39:1315-22. Linch DC, Cunnningham D. De novo treatment of diffuse
31. Lyman GH, Dale DC, Friedberg J, Crawford J, Fisher RI. large B-cell lymphoma with rituximab, cyclophosphamide,
Incidence and predictors of low chemotherapy dose-intensity vincristine, gemcitabine, and prednisolone in patients with
in aggressive non-Hodgkin’s lymphoma: a nationwide study. cardiac comorbidity: a United Kingdom National Cancer
J Clin Oncol 2004;22:4302-11. Research Institute trial. J Clin Oncol 2014;32:282-7.
32. Habermann TM, Weller EA, Morrison VA, Gascoyne RD,
Cassileth PA, Cohn JB, Dakhil SR, Woda B, Fisher RI,
Peterson BA, Horning SJ. Rituximab-CHOP versus CHOP How to cite this article: Zeeneldin AA, Sallam YA, Gaber AA,
alone or with maintenance rituximab in older patients with Shaheen AA. Non-anthracycline chemotherapy associated with a
diffuse large B-cell lymphoma. J Clin Oncol 2006;24:3121-7. poor outcome in elderly Egyptian patients with diffuse large B-cell
non-Hodgkin lymphoma. J Cancer Metastasis Treat 2015;1:76-83.
33. World Health Organization Assesses the World’s Health
Systems. World Health Report; 2000. Available from: http:// Received: 02-11-2014; Accepted: 08-04-2015.
www.who.int/whr/2000/media_centre/press_release/en/. Source of Support: Nil, Confl ict of Interest: None declared.

Journal of Cancer Metastasis and Treatment ¦ Volume 1 ¦ Issue 2 ¦ July 15, 2015 ¦ 83